StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Cash equivalents & AFS marketable debt securities by Quarter

Cash equivalents & AFS marketable debt securities — Total amortized cost ($M) ($M)

QuarterlyAnnual

Moderna Cash equivalents & AFS marketable debt securities: $5,202M in Q2 2026, down 16.5% from a year earlier.

Latest, Q2 2026
5,202
Period ended Jun 30, 2026
Change on a year earlier
-16.5%
6,227 in Q2 2025
History
32 quarters
Since Q1 2018
Sources
30
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 5 (Cash, Cash Equivalents and Marketable Securities).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCash equivalents & AFS marketable debt securities — Total amortized cost ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20265,202-16.5%Form 10-Q (filed 2026-07-31) ↗
Q1 2026Mar 31, 20265,556-18.0%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 20255,533-27.3%Form 10-Q (filed 2026-07-31) ↗
Q3 2025Sep 30, 20255,510-27.3%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 20256,227-26.1%Form 10-Q (filed 2025-08-01) ↗
Q1 2025Mar 31, 20256,775-33.8%Form 10-Q (filed 2025-05-01) ↗
Q4 2024Dec 31, 20247,614-27.6%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 20247,577-25.6%Form 10-Q (filed 2024-11-07) ↗
Q2 2024Jun 30, 20248,429-24.0%Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 202410,232-22.9%Form 10-Q (filed 2024-05-02) ↗
Q4 2023Dec 31, 202310,519-32.0%Form 10-K (filed 2025-02-21) ↗
Q3 2023Sep 30, 202310,182-29.9%Form 10-Q (filed 2023-11-03) ↗
Q2 2023Jun 30, 202311,098-28.7%Form 10-Q (filed 2023-08-03) ↗
Q1 2023Mar 31, 202313,265-8.6%Form 10-Q (filed 2023-05-04) ↗
Q4 2022Dec 31, 202215,479+43.7%Form 10-K (filed 2024-02-23) ↗
Q3 2022Sep 30, 202214,525+48.1%Form 10-Q (filed 2022-11-03) ↗

Cite this data

StockData. (2026). Moderna Cash equivalents & AFS marketable debt securities ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/afs-amort-cost

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.